Brief: Replimune Group Says Rp1 Plus Nivolumab Achieves Median Overall Survival Of 32.9 Months In Anti-Pd-1-Failed Melanoma
30/05/2026 13:11
BRIEF-Replimune Group Says Rp1 Plus Nivolumab Achieves Median Overall Survival Of 32.9 Months In Anti-Pd-1-Failed Melanoma May 30 (Reuters) - Replimune Group Inc REPL.O:
REPLIMUNE GROUP - RP1 PLUS NIVOLUMAB ACHIEVES MEDIAN OVERALL SURVIVAL OF 32.9 MONTHS IN ANTI-PD-1-FAILED MELANOMA
Source text: ID:nGNX8LjXdy
Further company coverage: REPL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Replimune
See all newsTrump picks White House adviser Heidi Overton to run FDA, source says (updated)
Brief: Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed
Brief: Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update
Replimune Q1 net loss narrows as expenses decline
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly